Below are current clinical trials.13 studies in Rectal cancer
(open studies only).
Filter this list of studies by location, status and more.
The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation therapy) prior to surgery. Although radiation therapy to the pelvis has been a standard and important part of treatment for rectal cancer and has been shown to decrease the risk of the cancer coming back in the same area in the pelvis, some patients experience undesirable side effects from the radiation and there have been important advances in chemotherapy, surgery, and radiation which may be of benefit. The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen known as FOLFOX, (the drugs 5-fluorouracil (5-FU), oxaliplatin and leucovorin) and selective use of the standard treatment, depending on response to the FOLFOX. The drugs in the FOLFOX regimen are all FDA (Food and Drug Administration) approved and have been used routinely to treat patients with advanced colorectal cancer.
The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of lower extremity proximal deep vein thrombosis (DVT), asymptomatic lower extremity proximal DVT, symptomatic upper extremity DVT, symptomatic non-fatal pulmonary embolism (PE), incidental PE, and venous thromboembolism (VTE)-related death in ambulatory adult patients with various cancer types receiving systemic cancer therapy who are at high risk of developing a VTE.
This study will assess the efficacy and outcomes of PD-1 blockade in patients with mismatch repair deficient colorectal cancer.
Scottsdale/Phoenix, Ariz., Rochester, Minn.
This is an open label, multi-center, Phase Ib dose escalation study of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib. A study cycle will consist of daily and continuous oral administration of BBI608 for four weeks (28 days) in combination with FOLFOX6 with and without bevacizumab, or CAPOX or FOLFIRI with and without bevacizumab, or regorafenib.
Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing cancer from non-cancer.
The purpose of this study is to collect blood and stool samples to validate and improve the performance of stool and blood DNA markers for inflammatory bowel disease and colorectal neoplasia critical to the long-term goal of improving effectiveness of neoplasia detection in patients using non-invasive biomarkers to assist colonoscopy and radiographic screening.
The purpose of the study is to measure high grade (3-5) toxicity of regorafenib and to monitor the impact of treatment with regorafenib on the quality of life in older adults with metastatic colorectal cancer.
To determine whether PET/MRI can accurately predict complete pathologic response from neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer
This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor cancer with no evidence of disease after surgery and standard therapy. Subjects will be enrolled into one of six treatment arms. Subjects will be assessed according to standard of care. Restaging and imaging studies will be performed to assess disease relapse per NCCN guidelines. RECIST will be used to validate the findings in cases of relapse.
Scottsdale/Phoenix, Ariz., Rochester, Minn.
In this study, participants with MSI-H or dMMR advanced colorectal carcinoma will be randomly assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for the treatment of advanced colorectal carcinoma. The primary study hypothesis is that pembrolizumab will prolong progression-free survival (PFS) compared to current SOC chemotherapy.
April 29, 2017
- AskMayoExpert. Colorectal cancer. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
- Bailey HR, et al., eds. Management of rectal cancer. In: Colorectal Surgery. Philadelphia, Pa.: Saunders Elsevier; 2013. http://www.clinicalkey.com. Accessed Jan. 4, 2017.
- Rectal cancer treatment (PDQ). National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/treatment/rectal/HealthProfessional. Accessed Dec. 30, 2016.
- Fischer J, et al. Outcome for stage II and III rectal and colon cancer equally good after treatment improvement over three decades. International Journal of Colorectal Disease. 2015;30:797.
- Peres-Ruiz E, et al. Immunological landscape and clinical management of rectal cancer. Frontiers in Immunology. 2016;7:1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761957/. Accessed Feb. 22, 2017.
- Niederhuber JE, et al., eds. Cancer of the rectum. In: Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. http://www.clinicalkey.com. Accessed Jan. 4, 2017.
- Etzioni DA, et al. Patient survival after surgical treatment of rectal cancer: Impact of surgeon and hospital characteristics. Cancer. 2014;120:2472.
- Renouf DJ, et al. Improvements in 5-year outcomes of stage II/III rectal cancer relative to colon cancer. American Journal of Clinical Oncology. 2013;36:558.
- Colorectal cancer. American Cancer Society. https://www.cancer.org/cancer/colon-rectal-cancer.html. Accessed Jan. 4, 2017.
- Macrae FA, et al. Clinical presentation, diagnosis, and staging of colorectal cancer. http://www.uptodate.com/home. Accessed Feb. 4, 2016.
- Ryan DP, et al. Overview of the management of rectal adenocarcinoma. http://www.uptodate.com/home. Accessed Feb. 4, 2016.
- Mahipal A, et al. Role of biologics in first-line treatment of colorectal cancer. Journal of Oncology Practice. 2016:12:1219.
- Holman FA, et al. Results of a pooled analysis of IOERT containing multimodality treatment for locally recurrent rectal cancer: Results of 565 patients of two major treatment centers. European Journal of Surgical Oncology. 2017;43:107.
- Holman FA, et al. Results of intraoperative electron beam radiotherapy containing multimodality treatment for locally unresectable T4 rectal cancer: A pooled analysis of the Mayo Clinic Rochester and Catharina Hospital Eindhoven. Journal of Gastrointestinal Oncology. 2016;7:903.
- Larson DW (expert opinion). Mayo Clinic, Rochester, Minn. Nov. 30, 2016.